Thank you to those who attended our webinar, ‘Streamlining your drug development workflow using purge calculations’.
We were delighted to have Senior Principal Scientist Andy Teasdale presenting . Andy is the chair of AstraZeneca’s Impurity advisory Board, and has developed a wealth of knowledge over the last 30 years working in the pharmaceutical industry. He is leading AstraZeneca expert for a number of key impurity areas, including mutagenic impurities. Andy described the concept of purge factors and purge scoring for controlling potentially mutagenic impurities outside of the lab.
Lhasa Limited Senior Scientist, Natasha Hill has worked on our in silico tool for controlling potentially mutagenic impurities – ‘Mirabilis’ – since the project inception. She presented on identifying alerts and predicting reactivity, solubility, and volatility purge factors using Mirabilis.
Sarah Sämann is Drug Substance Lead for Small Molecules Development at Merck. She is collaboration lead with internal and external contract manufacturing organisations (CMOs), for clinical phases and until validation. She is involved with intermediates and active pharmaceutical ingredient (API) supply under current good manufacturing practice (cGMP). She also manages strategy for scale-up and chemical process development. Sarah presented a real-life case study using Mirabilis within the pharmaceutical industry.